138 related articles for article (PubMed ID: 34049853)
1. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
Rimar D; Slobodin G; Paz A; Henig I; Zuckerman T
Ann Rheum Dis; 2021 Oct; 80(10):1354-1355. PubMed ID: 34049853
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
3. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
4. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
5. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
6. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
7. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
Albach FN; Burmester GR; Biesen R
Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
[No Abstract] [Full Text] [Related]
8. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
[TBL] [Abstract][Full Text] [Related]
9. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
Redjoul R; Le Bouter A; Beckerich F; Fourati S; Maury S
Lancet; 2021 Jul; 398(10297):298-299. PubMed ID: 34270933
[No Abstract] [Full Text] [Related]
10. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.
Marion O; Del Bello A; Abravanel F; Couat C; Faguer S; Esposito L; Hebral AL; Izopet J; Kamar N
Ann Intern Med; 2021 Sep; 174(9):1336-1338. PubMed ID: 34029487
[No Abstract] [Full Text] [Related]
11. Negative SARS-CoV-2 antibodies, T-cell response and virus neutralization following full vaccination in a renal transplant recipient: a call for vigilance.
Pedersen RM; Tornby DS; Bistrup C; Johansen IS; Andersen TE; Justesen US
Clin Microbiol Infect; 2021 Sep; 27(9):1371-1373. PubMed ID: 34111582
[No Abstract] [Full Text] [Related]
12. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
Connolly CM; Boyarsky BJ; Ruddy JA; Werbel WA; Christopher-Stine L; Garonzik-Wang JM; Segev DL; Paik JJ
Ann Intern Med; 2021 Sep; 174(9):1332-1334. PubMed ID: 34029488
[No Abstract] [Full Text] [Related]
13. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
Winthrop KL; Whitley RJ; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198
[No Abstract] [Full Text] [Related]
15. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.
Werbel WA; Boyarsky BJ; Ou MT; Massie AB; Tobian AAR; Garonzik-Wang JM; Segev DL
Ann Intern Med; 2021 Sep; 174(9):1330-1332. PubMed ID: 34125572
[No Abstract] [Full Text] [Related]
16. Confronting the Delta Variant of SARS-CoV-2, Summer 2021.
Del Rio C; Malani PN; Omer SB
JAMA; 2021 Sep; 326(11):1001-1002. PubMed ID: 34406361
[No Abstract] [Full Text] [Related]
17. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.
Pasikhova Y; Morrison AR; Katzman JH; Syed M
Cancer Control; 2022; 29():10732748211070720. PubMed ID: 35001670
[TBL] [Abstract][Full Text] [Related]
19. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.
Yi SG; Knight RJ; Graviss EA; Moore LW; Nguyen DT; Ghobrial RM; Gaber AO; Huang HJ
Transplantation; 2021 Jul; 105(7):e72-e73. PubMed ID: 33741844
[No Abstract] [Full Text] [Related]
20. T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: "Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.".
Bsteh G; Sellner J
EBioMedicine; 2021 Dec; 74():103692. PubMed ID: 34773893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
